Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 16, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a protein called Annexin A2 (ANXA2) and its role in a condition known as Antiphospholipid Syndrome (APS). APS can lead to blood clots and other serious complications. Researchers want to see how much ANXA2 is present on certain immune cells in patients with APS. Understanding this could help explain some of the problems related to APS and potentially lead to better treatments.
To participate in the trial, you must be an adult (18 years or older) diagnosed with APS according to specific medical guidelines. Unfortunately, people with certain other health issues, such as cancers or other autoimmune diseases, cannot join. If you are eligible and decide to participate, you can expect to have your blood tested to measure the levels of ANXA2 on your immune cells. This research is important because it may reveal new ways that APS affects the body, which could eventually help improve care for patients with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • APS patients who fulfilled the revised criteria for APS
- Exclusion Criteria:
- • Patients less than 18 years old
- • Solid and hematological malignancies
- • Other autoimmune diseases
- • Cirrhosis
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported